Around June 17, 2026, OpenAI disclosed a case in which its general-purpose large language model GPT-5.4 improved a synthesis reaction used in drug discovery, turning an AI-generated idea into a result validated by experiment. The model supported the workflow from literature review to hypothesis generation, experimental design and data analysis, and concrete yield gains were confirmed through a robotic synthesis platform working with a specialized lab.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.